CO5271660A1 - Antagonistas del receptor de la il-8 - Google Patents

Antagonistas del receptor de la il-8

Info

Publication number
CO5271660A1
CO5271660A1 CO01019686A CO01019686A CO5271660A1 CO 5271660 A1 CO5271660 A1 CO 5271660A1 CO 01019686 A CO01019686 A CO 01019686A CO 01019686 A CO01019686 A CO 01019686A CO 5271660 A1 CO5271660 A1 CO 5271660A1
Authority
CO
Colombia
Prior art keywords
alkyl
optionally substituted
chloro
heterocyclic
aryl
Prior art date
Application number
CO01019686A
Other languages
English (en)
Inventor
Qi Jin
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5271660A1 publication Critical patent/CO5271660A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)

Abstract

Un compuesto de fórmula (I): <EMI FILE="01019686_1" ID="1" IMF=JPEG >en la que Rb se selecciona Independientemente del grupo que consta de hidrógeno, NR6R7, OH, ORa, alquilo de C1-5, arilo, aril-alquilo de C1-4, aril-alquenilo de C2-4, cicloalquil, cicloalquilo-alquilo de C1-5, heteroarilo, heteroaril-alquilo de C1-4, heteroaril-alquenilo de C2-4, heterociclico, heterocíclico-alquilo de C1-4 y un resto heterocíclico-alquenilo de C2-4, restos todos que pueden estar opcionalmente sustituidos de una a tres veces independientemente por un sustituyente seleccionado del grupo que consta de halógeno, nitro, alquilo de C1-4 halosustituido, alquilo de C1-4, amino, amina mono- o di-alquilo de C1-4 sustituida, ORa, C(O)Ra, NRaC(O)ORa, OC(O)NR6R7, hidroxi, NR9C(O)Ra, S(O)mRa, C(O)NR6R7, C(O)OH, C(O)ORa, S(O)2NR6R7 y NHS(O)2Ra; o los dos sustituyentes Rb se unen para formar un anillo de 3-10 miembros opcionalmente sustituido y que contiene, además de carbono, independientemente, de 1 a 3 restos opcionalmente sustituidos seleccionados del grupo que consta de NRa, O, S, SO y SO2; Ra se selecciona del grupo que consta de alquilo, arilo, aril-alquilo de C1-4, heteroarilo, heteroaril-alquilo de C1-4, heterociclo, COORa, y un resto heterociclo-alquilo de C2-4, restos todos que pueden estar opcionalmente sustituidos ;m es un número entero que tiene un valor de 1 a 3;m´ es 0 o un número entero que tiene un valor de 1 ón es un número entero que tiene un valor de 1 a 3;q es 0, o un número entero que tiene un valor de 1 a 10;t es 0, o un número entero que tiene un valor de 1 o 2;s es un número entero que tiene un valor de 1 a 3;R1 se selecciona independientemente del grupo que consta de hidrógeno, halógeno, nitro, ciano, alquilo de C1-10, alquilo de C1-10 halosustituido, alquenilo de C2-10, alcoxi de C1-10, alcoxi de C1-10, halosustituido, azida, S(O)tR4, (CR8R8)qS(O)tR4, hidroxi, alquilo de C1-4 hidroxi sustituido, - 2 - arilo, aril-alquilo de C1-4 , aril-alquenilo de C2-10, ariloxi, aril-alquiloxi de C1-4, heteroarilo, heteroarilalquilo, heteroaril-alquenilo de C2-10, heteroaril-alquiloxi de C1-4, heterocíclico, heterocíclico-alquilo de C1-4 , heterocíclico-alquiloxi de C1-4, heterocíclico-alquenilo de C2-10, (CR8R8)qNR4R5, (CR8R8)qC(O)NR4R5, alquenilo de C2-10 C(O)NR4R5, (CR8R8)qC(O)NR4R10, S(O)3R8, (CR8R8)qC(O)R11, alquenilo de C2-10C(O)R11, alquenilo de C2-10C(O)OR11, (CR8R8)qC(O)OR11, (CR8R8)qOC(O)R11, (CR8R8)qNR4C(O)R11, (CR8R8)qC(NR4)NR4R5, (CR8R8)qNR4C(NR5)R11, (CR8R8)qNHS(O)2R13, y (CR8R8)qS(O)2NR4R5, o dos restos R1 conjuntamente pueden formar O-(CH2)sO o un anillo saturado o insaturado de 5 a 6 miembros, tal que los restos alquilo, arilo, arilalquilo, heteroarilo o heterocíclico puede estar opcionalmente sustituidos;R4 y R5 se seleccionan independientemente del grupo que consta de hidrógeno, alquilo C1-4, opcionalmente sustituido, arilo opcionalmente sustituido, aril-alquilo de C1-4, opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroaril-alquilo de C1-4, opcionalmente sustituido, heterocíclico; y heterocíclico-alquilo de C1-4, o R4 y R5 junto con el nitrogeno al estan unidos forman un anillo de 5 a 7 miembros que opcionalmente puede comprender un heteroátomo adicional seleccionado de O, N y S;R6 y R7 se seleccionan independientemente del grupo que consta de hidrógeno, alquilo de C1-4, heteroarilo, arilo, alquilarilo y alquilo de C1-4-heteroalquilo; o R6 y R7 junto con el nitrógeno al que estan unidos forman un anillo de 5 a 7 miembros, anillo que opcionalmente puede contener un heteroátomo adicional que se selecciona del grupo que consta de oxígeno, nitrógeno o azufre y anillo que puede estar opcionalmente sustituido;Y se selecciona del grupo que consta de furano, tiofeno, pirrol, oxazol, imidazol, Tiazol, tieno(2,3b) piridina, pirazol, isooxazol, 1,2,3- o 1,2,4-oxadiazol, 1, 2, 3- o 1, 2, 4-triazol, 1, 2, 3- o 1, 2, 4-tiadiazol, piridina, piridina-N-óxido, pirimidina, piridazina, pirazina, 1, 3, 5,- o 1, 2, 3- o 1, 2, 4-triazina, 1,2,4,5-tetrazina, indol benzofurano, indazol, bencimidazol, quinolina, isoquinolina, cinolina, ftalazina, quinazolina y quinoxalina, restos todos que pueden estar 1-3 veces sustituidos con R1;R8 es hidrógeno o alquilo de C1-4;R9 es hidrógeno o alquilo de C1-4 ;R10 es alquilo de C1-10 C(O)2R8;R11 se selecciona del grupo que consta de hidrógeno, alquilo de C1-4 opcionalmente sustituido, arilo opcionalmente sustituido, aril-alquilo de C1-4 opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroaril-alquilo de C1-4 opcionalmente sustituido, heterocíclico opcionalmente sustituido; y heterocíclico-alquilo de C1-4 opcionalmente sustituido; yR13 se selecciona del grupo que consta de alquilo de C1-4, arilo, aril-alquilo de C1-4, heteroarilo, heteroaril-alquilo de C1-4 , heterocíclico y heterocíclico-alquilo de C1-4 ;o una de sus sales farmacéuticamente aceptables. El compuesto según la reivindicación 1, que es:N-(3-aminosulfonil-4-cloro-2-hidroxifenil) -N´- (piridin-2-il) urea;N-(-3-aminosulfonil-4-cloro-2-hidroxifenil)-N-(2-cloro-piridin-3-il)urea;N-(3-aminosulfonil-4-cloro-2-hidroxifenil)-N´-(1-fenil-1H-1,2,3-triazol-5-il)urea;N-(3-aminosulfonil-4-cloro-2-hidroxifenil)-N´-(1,3-dimetilpirazol-5-il)urea;N-(3-aminosulfonil-4-cloro-2-hidroxifenil)-N´-(1-metilpirazol-5-il)urea; yN-(3-aminosulfonil-4-cloro-2-hidroxifenil)-N´-(-2-metil-piridin-3-il)ureaN-(3-aminosulfonil-4-cloro-2-hidroxifenil)-N´-(3,5-dimetilisoxazol-4-il)urea;N-(3-aminosulfonil-4-cloro-2-hidroxifenil)-N´-(1-N-óxido-piridin-3-il)urea;N-(3-aminosulfonil-4-cloro-2-hidroxifenil)-N´-(-2-cloro-1-N-óxido-piridin-3-il)urea;N-(3-aminosulfonil-4-cloro-2-hidroxifenil)-N´-(3-benziloxitieno[2,3-b]piridin-2-il)urea;N-(3-aminosulfonil-4-cloro-2-hidroxifenil)-N´-(3-metilisoxazol-4-il)urea;N-(3-aminosulfonil-4-cloro-2-hidroxifenil)-N´-(-5-metilisoxazol-4-il)urea.
CO01019686A 2000-03-10 2001-03-12 Antagonistas del receptor de la il-8 CO5271660A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18841000P 2000-03-10 2000-03-10

Publications (1)

Publication Number Publication Date
CO5271660A1 true CO5271660A1 (es) 2003-04-30

Family

ID=22693024

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01019686A CO5271660A1 (es) 2000-03-10 2001-03-12 Antagonistas del receptor de la il-8

Country Status (26)

Country Link
US (1) US6608077B2 (es)
EP (1) EP1261336B1 (es)
JP (1) JP2003535820A (es)
KR (1) KR20020083174A (es)
CN (1) CN1635979A (es)
AR (1) AR030273A1 (es)
AT (1) ATE353215T1 (es)
AU (2) AU4560601A (es)
BR (1) BR0109002A (es)
CA (1) CA2402891A1 (es)
CO (1) CO5271660A1 (es)
CY (1) CY1106514T1 (es)
CZ (1) CZ20023007A3 (es)
DE (1) DE60126480T2 (es)
DK (1) DK1261336T3 (es)
ES (1) ES2280350T3 (es)
HU (1) HUP0302003A3 (es)
IL (1) IL151431A0 (es)
MX (1) MXPA02008818A (es)
MY (1) MY133845A (es)
NO (1) NO20024193L (es)
NZ (1) NZ520912A (es)
PL (1) PL363118A1 (es)
PT (1) PT1261336E (es)
WO (1) WO2001068568A2 (es)
ZA (1) ZA200207216B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030689A1 (es) * 2000-03-14 2003-09-03 Smithkline Beecham Corp Compuestos de 3-aminosulfonil-2-hidroxifenil urea, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos en la manufactura de medicamentos para tratar enfermedades mediadas por quimioquinas
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
AR030753A1 (es) * 2000-09-25 2003-09-03 Smithkline Beecham Corp Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
GB0124848D0 (en) * 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US7056925B2 (en) 2002-08-13 2006-06-06 Abbott Laboratories Urea kinase inhibitors
AR041834A1 (es) * 2002-10-29 2005-06-01 Smithkline Beecham Corp Compuesto de difenilurea sustituido con sulfonamida, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
US7511042B2 (en) 2003-12-03 2009-03-31 Boehringer Ingelheim Pharmaceuticals, Inc. Triazole compounds
US20070249625A1 (en) * 2004-10-20 2007-10-25 Jakob Busch-Petersen Il-8 Receptor Antagonists
KR101376472B1 (ko) * 2006-04-21 2014-03-19 글락소스미스클라인 엘엘씨 Ｉｌ­８ 수용체 길항제
WO2007124423A2 (en) * 2006-04-21 2007-11-01 Smithkline Beecham Corporation Il-8 receptor antagonists
TW200817006A (en) * 2006-06-23 2008-04-16 Smithkline Beecham Corp IL-8 receptor antagonist
CN107522641B (zh) * 2016-06-22 2020-05-05 复旦大学 联芳基脲类衍生物或其盐及其制备方法和用途
WO2017219935A1 (zh) 2016-06-22 2017-12-28 复旦大学 联芳基脲类衍生物或其盐及其制备方法和用途
US11136315B2 (en) 2018-01-11 2021-10-05 Medshine Discovery Inc. CXCR2 antagonist

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0809492A4 (en) 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
KR20000022274A (ko) * 1996-06-27 2000-04-25 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 Il-8 수용체 길항제
UY25842A1 (es) * 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8

Also Published As

Publication number Publication date
HUP0302003A3 (en) 2005-06-28
AU2001245606B2 (en) 2006-03-09
DE60126480D1 (de) 2007-03-22
EP1261336A2 (en) 2002-12-04
EP1261336A4 (en) 2004-12-15
KR20020083174A (ko) 2002-11-01
ZA200207216B (en) 2004-07-21
AU4560601A (en) 2001-09-24
NO20024193D0 (no) 2002-09-03
US6608077B2 (en) 2003-08-19
MY133845A (en) 2007-11-30
CN1635979A (zh) 2005-07-06
CA2402891A1 (en) 2001-09-20
MXPA02008818A (es) 2006-06-05
CZ20023007A3 (cs) 2003-04-16
AR030273A1 (es) 2003-08-20
CY1106514T1 (el) 2012-01-25
ES2280350T3 (es) 2007-09-16
JP2003535820A (ja) 2003-12-02
HUP0302003A2 (hu) 2003-11-28
PT1261336E (pt) 2007-03-30
DK1261336T3 (da) 2007-06-04
DE60126480T2 (de) 2007-06-14
WO2001068568A3 (en) 2002-03-21
WO2001068568A2 (en) 2001-09-20
IL151431A0 (en) 2003-04-10
US20030055286A1 (en) 2003-03-20
BR0109002A (pt) 2004-08-17
EP1261336B1 (en) 2007-02-07
PL363118A1 (en) 2004-11-15
NO20024193L (no) 2002-09-03
NZ520912A (en) 2005-02-25
ATE353215T1 (de) 2007-02-15

Similar Documents

Publication Publication Date Title
CO5271660A1 (es) Antagonistas del receptor de la il-8
RU2216533C2 (ru) Новые трициклические производные (варианты), фармацевтическая композиция (варианты), способ подавления иммуной реакции или лечения и/или предупреждения аллергических заболеваний (варианты)
CO5280070A1 (es) Compuestos, composiciones farmaceuticas de indazol y metodos para mediar o inhibir la proliferacion celular
AR097445A2 (es) Ésteres oxigenados de ácidos 4-yodo fenilamino benzhidroxámicos
RU2011152891A (ru) Диарилгидантоины
CA2445344A1 (en) Heterocyclic compound derivatives and medicines
AR032453A1 (es) Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos
BR9307595A (pt) Composto, processo para sua preparação, composição herbicida, e, processo para danificar severamente ou exterminar plantas indesejáveis
JP2002524570A5 (ja) Ｍｄｍ２およびｐ５３間相互作用の阻害剤としてのピペラジン−４−フェニル誘導体
CO5170518A1 (es) Compuestos n-(benzocicloalquilo) derivados de amino aralifaticos
CO5601012A2 (es) Compuestos que modulan la actividad de ppar
HUP0302367A2 (hu) HIV Integráz inhibitorokként hasznos aza- és poliazanaftalenil-karboxamidok, ezeket tartalmazó gyógyszerkészítmények
JP2006517220A5 (es)
RU2006137272A (ru) Производные 2-фенилпропионовой кислоты и содержащие их фармацевтические композиции
AR088921A2 (es) PROCESO PARA LA PREPARACION DE DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTA mGluR5, COMPOSICIONES Y USO DE LOS COMPUESTOS
DK1200390T3 (da) Fremstilling af N-substituerede 2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamider
CO5650165A2 (es) Procedimientos para la preparacion de derivados de benzoimidazol
CO5080729A1 (es) Benzimidazoles, su preparacion y medicamentos que los contienen
HRP20090264T1 (en) Phenyl-piperazin methanone derivatives
NO952208L (no) Amin-derivater
CA2413000A1 (en) Five-membered ring compounds
CO5611103A2 (es) Derivados de bencensulfonamida como agentes antisicoticos
CO5261565A1 (es) Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2-tiazolil)-carboxamida de cinasas dependientes de ciclina
AR077156A1 (es) Inhibidores de transportador de glicina-1
PE20212323A1 (es) Formulaciones farmaceuticas

Legal Events

Date Code Title Description
FC Application refused